210 related articles for article (PubMed ID: 28108509)
21. Enhanced antitumor immunity through sequential targeting of PI3Kδ and LAG3.
Lauder SN; Smart K; Kersemans V; Allen D; Scott J; Pires A; Milutinovic S; Somerville M; Smart S; Kinchesh P; Lopez-Guadamillas E; Hughes E; Jones E; Scurr M; Godkin A; Friedman LS; Vanhaesebroeck B; Gallimore A
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33093155
[TBL] [Abstract][Full Text] [Related]
22. β-Adrenergic Signaling Impairs Antitumor CD8
Nissen MD; Sloan EK; Mattarollo SR
Cancer Immunol Res; 2018 Jan; 6(1):98-109. PubMed ID: 29146881
[TBL] [Abstract][Full Text] [Related]
23. Autologous tumor vaccine modified with recombinant new castle disease virus expressing IL-7 promotes antitumor immune response.
Zhao L; Mei Y; Sun Q; Guo L; Wu Y; Yu X; Hu B; Liu X; Liu H
J Immunol; 2014 Jul; 193(2):735-45. PubMed ID: 24943214
[TBL] [Abstract][Full Text] [Related]
24. Blockade of β-Adrenergic Receptors Improves CD8
Daher C; Vimeux L; Stoeva R; Peranzoni E; Bismuth G; Wieduwild E; Lucas B; Donnadieu E; Bercovici N; Trautmann A; Feuillet V
Cancer Immunol Res; 2019 Nov; 7(11):1849-1863. PubMed ID: 31527069
[TBL] [Abstract][Full Text] [Related]
25. CD11c(high)CD8+ regulatory T cell feedback inhibits CD4 T cell immune response via Fas ligand-Fas pathway.
Chen Z; Han Y; Gu Y; Liu Y; Jiang Z; Zhang M; Cao X
J Immunol; 2013 Jun; 190(12):6145-54. PubMed ID: 23677464
[TBL] [Abstract][Full Text] [Related]
26. CD4+ T cells are able to promote tumor growth through inhibition of tumor-specific CD8+ T-cell responses in tumor-bearing hosts.
den Boer AT; van Mierlo GJ; Fransen MF; Melief CJ; Offringa R; Toes RE
Cancer Res; 2005 Aug; 65(15):6984-9. PubMed ID: 16061684
[TBL] [Abstract][Full Text] [Related]
27. Combination of docetaxel and recombinant vaccine enhances T-cell responses and antitumor activity: effects of docetaxel on immune enhancement.
Garnett CT; Schlom J; Hodge JW
Clin Cancer Res; 2008 Jun; 14(11):3536-44. PubMed ID: 18519787
[TBL] [Abstract][Full Text] [Related]
28. Compensation between CSF1R+ macrophages and Foxp3+ Treg cells drives resistance to tumor immunotherapy.
Gyori D; Lim EL; Grant FM; Spensberger D; Roychoudhuri R; Shuttleworth SJ; Okkenhaug K; Stephens LR; Hawkins PT
JCI Insight; 2018 Jun; 3(11):. PubMed ID: 29875321
[TBL] [Abstract][Full Text] [Related]
29. CD8+ Foxp3+ regulatory T cells mediate immunosuppression in prostate cancer.
Kiniwa Y; Miyahara Y; Wang HY; Peng W; Peng G; Wheeler TM; Thompson TC; Old LJ; Wang RF
Clin Cancer Res; 2007 Dec; 13(23):6947-58. PubMed ID: 18056169
[TBL] [Abstract][Full Text] [Related]
30. PI3Kδ Is a Therapeutic Target in Hepatocellular Carcinoma.
Ko E; Seo HW; Jung ES; Ju S; Kim BH; Cho H; Kim YJ; Park YM; Kim JS; Jung G
Hepatology; 2018 Dec; 68(6):2285-2300. PubMed ID: 30300952
[TBL] [Abstract][Full Text] [Related]
31. Combination of CTL-associated antigen-4 blockade and depletion of CD25 regulatory T cells enhance tumour immunity of dendritic cell-based vaccine in a mouse model of colon cancer.
Saha A; Chatterjee SK
Scand J Immunol; 2010 Feb; 71(2):70-82. PubMed ID: 20384858
[TBL] [Abstract][Full Text] [Related]
32. Enhanced Therapeutic Efficacy and Memory of Tumor-Specific CD8 T Cells by
Abu Eid R; Ahmad S; Lin Y; Webb M; Berrong Z; Shrimali R; Kumai T; Ananth S; Rodriguez PC; Celis E; Janik J; Mkrtichyan M; Khleif SN
Cancer Res; 2017 Aug; 77(15):4135-4145. PubMed ID: 28615225
[TBL] [Abstract][Full Text] [Related]
33. PI3Kδ inhibitors in cancer: rationale and serendipity merge in the clinic.
Fruman DA; Rommel C
Cancer Discov; 2011 Dec; 1(7):562-72. PubMed ID: 22586681
[TBL] [Abstract][Full Text] [Related]
34. HDAC5 controls the functions of Foxp3(+) T-regulatory and CD8(+) T cells.
Xiao H; Jiao J; Wang L; O'Brien S; Newick K; Wang LC; Falkensammer E; Liu Y; Han R; Kapoor V; Hansen FK; Kurz T; Hancock WW; Beier UH
Int J Cancer; 2016 May; 138(10):2477-86. PubMed ID: 26704363
[TBL] [Abstract][Full Text] [Related]
35. Therapy of Established Tumors with Rationally Designed Multiple Agents Targeting Diverse Immune-Tumor Interactions: Engage, Expand, Enable.
Fabian KP; Malamas AS; Padget MR; Solocinski K; Wolfson B; Fujii R; Abdul Sater H; Schlom J; Hodge JW
Cancer Immunol Res; 2021 Feb; 9(2):239-252. PubMed ID: 33355290
[TBL] [Abstract][Full Text] [Related]
36. The significance of Treg cells in defective tumor immunity.
Kosmaczewska A; Ciszak L; Potoczek S; Frydecka I
Arch Immunol Ther Exp (Warsz); 2008; 56(3):181-91. PubMed ID: 18512029
[TBL] [Abstract][Full Text] [Related]
37. iNOS expression in CD4+ T cells limits Treg induction by repressing TGFβ1: combined iNOS inhibition and Treg depletion unmask endogenous antitumor immunity.
Jayaraman P; Alfarano MG; Svider PF; Parikh F; Lu G; Kidwai S; Xiong H; Sikora AG
Clin Cancer Res; 2014 Dec; 20(24):6439-51. PubMed ID: 25278453
[TBL] [Abstract][Full Text] [Related]
38. Novel Cell-Penetrating Peptide-Based Vaccine Induces Robust CD4+ and CD8+ T Cell-Mediated Antitumor Immunity.
Derouazi M; Di Berardino-Besson W; Belnoue E; Hoepner S; Walther R; Benkhoucha M; Teta P; Dufour Y; Yacoub Maroun C; Salazar AM; Martinvalet D; Dietrich PY; Walker PR
Cancer Res; 2015 Aug; 75(15):3020-31. PubMed ID: 26116496
[TBL] [Abstract][Full Text] [Related]
39. CTLA-4 co-receptor impacts on the function of Treg and CD8+ T-cell subsets.
Rudd CE
Eur J Immunol; 2009 Mar; 39(3):687-90. PubMed ID: 19283722
[TBL] [Abstract][Full Text] [Related]
40. Cancer-associated fibroblast-targeted strategy enhances antitumor immune responses in dendritic cell-based vaccine.
Ohshio Y; Teramoto K; Hanaoka J; Tezuka N; Itoh Y; Asai T; Daigo Y; Ogasawara K
Cancer Sci; 2015 Feb; 106(2):134-42. PubMed ID: 25483888
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
